Literature DB >> 18070905

Sequence diversity of the Trypanosoma cruzi complement regulatory protein family.

M Beucher1, K A Norris.   

Abstract

As a central component of innate immunity, complement activation is a critical mechanism of containment and clearance of microbial pathogens in advance of the development of acquired immunity. Several pathogens restrict complement activation through the acquisition of host proteins that regulate complement activation or through the production of their own complement regulatory molecules (M. K. Liszewski, M. K. Leung, R. Hauhart, R. M. Buller, P. Bertram, X. Wang, A. M. Rosengard, G. J. Kotwal, and J. P. Atkinson, J. Immunol. 176:3725-3734, 2006; J. Lubinski, L. Wang, D. Mastellos, A. Sahu, J. D. Lambris, and H. M. Friedman, J. Exp. Med. 190:1637-1646, 1999). The infectious stage of the protozoan parasite Trypanosoma cruzi produces a surface-anchored complement regulatory protein (CRP) that functions to inhibit alternative and classical pathway complement activation (K. A. Norris, B. Bradt, N. R. Cooper, and M. So, J. Immunol. 147:2240-2247, 1991). This study addresses the genomic complexity of the T. cruzi CRP and its relationship to the T. cruzi supergene family comprising active trans-sialidase (TS) and TS-like proteins. The TS superfamily consists of several functionally distinct subfamilies that share a characteristic sialidase domain at their amino termini. These TS families include active TS, adhesions, CRPs, and proteins of unknown functions (G. A. Cross and G. B. Takle, Annu. Rev. Microbiol. 47:385-411, 1993). A sequence comparison search of GenBank using BLASTP revealed several full-length paralogs of CRP. These proteins share significant homology at their amino termini and a strong spatial conservation of cysteine residues. Alternative pathway complement regulation was confirmed for CRP paralogs with 58% (low) and 83% (high) identity to AAB49414. CRPs are functionally similar to the microbial and mammalian proteins that regulate complement activation. Sequence alignment of mammalian complement control proteins to CRP showed that these sequences are distinct, supporting a convergent evolutionary pathway. Finally, we show that a clonal line of T. cruzi expresses multiple unique copies of CRP that are differentially recognized by patient sera.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18070905      PMCID: PMC2223453          DOI: 10.1128/IAI.01104-07

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Sialidase-like Asp-boxes: sequence-similar structures within different protein folds.

Authors:  R R Copley; R B Russell; C P Ponting
Journal:  Protein Sci       Date:  2001-02       Impact factor: 6.725

Review 2.  Structure and flexibility of the multiple domain proteins that regulate complement activation.

Authors:  M D Kirkitadze; P N Barlow
Journal:  Immunol Rev       Date:  2001-04       Impact factor: 12.988

3.  Decay-accelerating factor (DAF), complement receptor 1 (CR1), and factor H dissociate the complement AP C3 convertase (C3bBb) via sites on the type A domain of Bb.

Authors:  Dennis E Hourcade; Lynne Mitchell; Lisa A Kuttner-Kondo; John P Atkinson; M Edward Medof
Journal:  J Biol Chem       Date:  2001-11-02       Impact factor: 5.157

4.  DNA-Based immunization with Trypanosoma cruzi complement regulatory protein elicits complement lytic antibodies and confers protection against Trypanosoma cruzi infection.

Authors:  P Sepulveda; M Hontebeyrie; P Liegeard; A Mascilli; K A Norris
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

5.  Trans-sialidase-like sequences from Trypanosoma congolense conserve most of the critical active site residues found in other trans-sialidases.

Authors:  Evelin Tiralongo; Ilka Martensen; Joachim Grötzinger; Joe Tiralongo; Roland Schauer
Journal:  Biol Chem       Date:  2003-08       Impact factor: 3.915

6.  A corresponding tyrosine residue in the C2/factor B type A domain is a hot spot in the decay acceleration of the complement C3 convertases.

Authors:  Lisa A Kuttner-Kondo; Megan P Dybvig; Lynne M Mitchell; Nasima Muqim; John P Atkinson; M Edward Medof; Dennis E Hourcade
Journal:  J Biol Chem       Date:  2003-10-15       Impact factor: 5.157

Review 7.  Proteases of the complement system.

Authors:  R B Sim; S A Tsiftsoglou
Journal:  Biochem Soc Trans       Date:  2004-02       Impact factor: 5.407

8.  Expression and purification of functional, recombinant Trypanosoma cruzi complement regulatory protein.

Authors:  Margaret Beucher; Wendell S F Meira; Vasthy Zegarra; Lúcia M C Galvão; Egler Chiari; Karen A Norris
Journal:  Protein Expr Purif       Date:  2003-01       Impact factor: 1.650

9.  In vivo role of complement-interacting domains of herpes simplex virus type 1 glycoprotein gC.

Authors:  J Lubinski; L Wang; D Mastellos; A Sahu; J D Lambris; H M Friedman
Journal:  J Exp Med       Date:  1999-12-06       Impact factor: 14.307

Review 10.  The relevance of complement to virus biology.

Authors:  Clare E Blue; O Brad Spiller; David J Blackbourn
Journal:  Virology       Date:  2004-02-20       Impact factor: 3.616

View more
  12 in total

Review 1.  Host-parasite interactions in trypanosomiasis: on the way to an antidisease strategy.

Authors:  Nicolas Antoine-Moussiaux; Philippe Büscher; Daniel Desmecht
Journal:  Infect Immun       Date:  2009-01-21       Impact factor: 3.441

Review 2.  Multigene families in Trypanosoma cruzi and their role in infectivity.

Authors:  Luis Miguel De Pablos; Antonio Osuna
Journal:  Infect Immun       Date:  2012-03-19       Impact factor: 3.441

3.  Specific humoral immunity versus polyclonal B cell activation in Trypanosoma cruzi infection of susceptible and resistant mice.

Authors:  Marianne A Bryan; Siobhan E Guyach; Karen A Norris
Journal:  PLoS Negl Trop Dis       Date:  2010-07-06

Review 4.  Genetic structure and expression of the surface glycoprotein GP82, the main adhesin of Trypanosoma cruzi metacyclic trypomastigotes.

Authors:  Paulo Roberto Ceridorio Correa; Esteban Mauricio Cordero; Luciana Girotto Gentil; Ethel Bayer-Santos; José Franco da Silveira
Journal:  ScientificWorldJournal       Date:  2013-02-04

5.  Genomic analyses, gene expression and antigenic profile of the trans-sialidase superfamily of Trypanosoma cruzi reveal an undetected level of complexity.

Authors:  Leandro M Freitas; Sara Lopes dos Santos; Gabriela F Rodrigues-Luiz; Tiago A O Mendes; Thiago S Rodrigues; Ricardo T Gazzinelli; Santuza M R Teixeira; Ricardo T Fujiwara; Daniella C Bartholomeu
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

Review 6.  A Brief View of the Surface Membrane Proteins from Trypanosoma cruzi.

Authors:  Ángel de la Cruz Pech-Canul; Victor Monteón; Rosa-Lidia Solís-Oviedo
Journal:  J Parasitol Res       Date:  2017-06-05

Review 7.  Trypanosoma cruzi Evades the Complement System as an Efficient Strategy to Survive in the Mammalian Host: The Specific Roles of Host/Parasite Molecules and Trypanosoma cruzi Calreticulin.

Authors:  Galia Ramírez-Toloza; Arturo Ferreira
Journal:  Front Microbiol       Date:  2017-09-01       Impact factor: 5.640

Review 8.  Trypanosoma Cruzi Genome: Organization, Multi-Gene Families, Transcription, and Biological Implications.

Authors:  Alfonso Herreros-Cabello; Francisco Callejas-Hernández; Núria Gironès; Manuel Fresno
Journal:  Genes (Basel)       Date:  2020-10-14       Impact factor: 4.096

Review 9.  Evasion of the Immune Response by Trypanosoma cruzi during Acute Infection.

Authors:  Mariana S Cardoso; João Luís Reis-Cunha; Daniella C Bartholomeu
Journal:  Front Immunol       Date:  2016-01-18       Impact factor: 7.561

10.  Biophysical and Biochemical Comparison of Extracellular Vesicles Produced by Infective and Non-Infective Stages of Trypanosoma cruzi.

Authors:  Lissette Retana Moreira; Alexa Prescilla-Ledezma; Alberto Cornet-Gomez; Fátima Linares; Ana Belén Jódar-Reyes; Jorge Fernandez; Ana Karina Ibarrola Vannucci; Luis Miguel De Pablos; Antonio Osuna
Journal:  Int J Mol Sci       Date:  2021-05-13       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.